Esperion Acquires Corstasis to Add Enbumyst Nasal Spray

Esperion Therapeutics has closed its acquisition of Corstasis Therapeutics Inc., a commercial-stage biopharmaceutical company developing outpatient therapies for edema tied to cardiovascular and hepatic and renal disease. Through the deal, Esperion integrates Corstasis’s Enbumyst (bumetanide) nasal spray into Esperion’s cardiovascular franchise.

Enbumyst is the first and only FDA-approved nasal spray loop diuretic for edema associated with congestive heart failure, as well as hepatic and renal disease in adults. Esperion plans to use its cardiovascular commercial infrastructure, including payer engagement, prescriber education, and field execution, to drive adoption and maximize patient access. The closing supports Esperion’s Vision 2040 strategy.